젬시타빈 염산염 시장

Global Gemcitabine Hydrochloride Market to Reach US$1.1 Billion by 2030

The global market for Gemcitabine Hydrochloride estimated at US$770.4 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Generic Drugs, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$694.3 Million by the end of the analysis period. Growth in the Branded Drugs segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$209.9 Million While China is Forecast to Grow at 8.4% CAGR

The Gemcitabine Hydrochloride market in the U.S. is estimated at US$209.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$227.0 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Gemcitabine Hydrochloride Market - Key Trends & Drivers Summarized

Why is Gemcitabine Hydrochloride Gaining Prominence in Cancer Treatment Protocols?

Gemcitabine Hydrochloride, a widely used chemotherapeutic agent, has become a cornerstone in the treatment of various cancers, including non-small cell lung cancer, pancreatic cancer, breast cancer, and ovarian cancer. Its efficacy as a nucleoside analog that interferes with DNA synthesis makes it a potent option for inhibiting tumor growth and proliferation. Over the past few years, there has been a marked increase in the adoption of Gemcitabine, driven by its effectiveness in combination therapy with other chemotherapeutic agents and targeted therapies. Studies have shown that combining Gemcitabine with platinum-based compounds, such as cisplatin, significantly improves patient outcomes, particularly in lung and bladder cancers. This has led to its inclusion in standard cancer treatment regimens across multiple oncology practices worldwide. Additionally, the relatively manageable side effect profile of Gemcitabine compared to other chemotherapies makes it a preferred option for elderly patients and those with comorbidities, further expanding its utility in clinical practice.

Regionally, the demand for Gemcitabine Hydrochloride is predominantly high in developed regions like North America and Europe, where oncology research and healthcare infrastructure are more advanced. In these regions, the emphasis on personalized medicine and tailored treatment protocols has led to a steady uptake of Gemcitabine in combination therapies. However, emerging markets such as Asia-Pacific and Latin America are expected to experience the fastest growth, owing to the rising incidence of cancer, improved healthcare access, and increasing government initiatives to combat cancer. Pharmaceutical companies are leveraging this trend by expanding their presence in these regions and investing in local production facilities to reduce costs and improve distribution efficiency. As a result, the global market for Gemcitabine Hydrochloride is poised for robust growth, driven by its proven clinical benefits, expanding therapeutic applications, and growing acceptance in both mono and combination therapies.

What Innovations in Drug Delivery and Formulation Are Driving Gemcitabine Hydrochloride’s Market Expansion?

Technological advancements in drug delivery and formulation are significantly shaping the Gemcitabine Hydrochloride market, making the drug more effective and easier to administer. Traditionally, Gemcitabine has been administered intravenously, which, although effective, comes with certain limitations such as inconvenience and potential for infusion-related complications. In response to these challenges, researchers and pharmaceutical companies are exploring alternative delivery mechanisms, including oral formulations, nanotechnology-based delivery systems, and localized drug delivery through transdermal patches or implants. These innovations are aimed at improving the bioavailability of Gemcitabine, reducing systemic toxicity, and enhancing patient compliance. For instance, nanotechnology-based delivery methods are being tested to ensure a more targeted approach, wherein the drug can be delivered directly to cancerous cells, minimizing exposure to healthy tissues and reducing side effects. Such advancements are expected to revolutionize the way Gemcitabine is administered, potentially making it suitable for a wider range of patients and indications.

Another critical area of research and development is the formulation of Gemcitabine conjugates and prodrugs. These novel formulations are designed to overcome the rapid degradation of Gemcitabine in the bloodstream, thereby enhancing its therapeutic efficacy and reducing the frequency of administration. Prodrug approaches, which involve modifying the chemical structure of Gemcitabine to make it more stable, are being extensively studied for their potential to improve patient outcomes. Additionally, combination therapies using Gemcitabine with newer immunotherapeutic agents and targeted therapies are being explored to develop more comprehensive treatment regimens for various cancers. Such research is leading to new patents and regulatory approvals, enabling pharmaceutical companies to introduce next-generation formulations of Gemcitabine Hydrochloride in the market. The continuous innovation in drug delivery and formulation technologies is expected to significantly contribute to the expansion of the Gemcitabine Hydrochloride market in the coming years.

How Are Market Dynamics and Healthcare Policies Shaping the Adoption of Gemcitabine Hydrochloride?

The adoption of Gemcitabine Hydrochloride is being influenced by a complex interplay of market dynamics and healthcare policies, which vary significantly across different regions. In developed markets like the United States and Western Europe, the strong focus on evidence-based medicine and clinical guidelines ensures that Gemcitabine remains a key component in standard cancer treatment regimens. The presence of well-established healthcare infrastructure, coupled with favorable reimbursement policies, supports the widespread use of this chemotherapeutic agent. Additionally, cancer care pathways in these regions often prioritize newer and more effective treatment options, and Gemcitabine’s proven track record in improving survival rates makes it a consistent choice for oncologists. Furthermore, the drug’s inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for multiple cancer types solidifies its status as a staple in oncology treatment protocols.

In contrast, the adoption of Gemcitabine in emerging markets is influenced by factors such as affordability, availability, and healthcare infrastructure constraints. Many developing countries are experiencing an increasing burden of cancer due to lifestyle changes, population aging, and improved detection rates. However, the high cost of cancer treatments remains a significant barrier. To address these challenges, governments in countries like China, India, and Brazil are implementing policies aimed at reducing the cost of essential oncology drugs, including Gemcitabine, through subsidies, local manufacturing, and generic production. The growing presence of biosimilar versions of Gemcitabine is also helping to reduce costs and increase accessibility in these regions. Additionally, the expansion of healthcare coverage and increased investment in cancer care infrastructure are expected to support the broader adoption of Gemcitabine Hydrochloride in these markets. These dynamics indicate that, while developed markets continue to drive high-value demand, emerging regions represent substantial growth opportunities for the Gemcitabine Hydrochloride market.

What Are the Key Growth Drivers Fueling the Expansion of the Gemcitabine Hydrochloride Market?

The growth in the global Gemcitabine Hydrochloride market is driven by several factors, including the rising prevalence of cancer, advancements in drug formulations, and increasing acceptance of combination therapies. The escalating burden of cancer globally, particularly lung, pancreatic, and breast cancers, is one of the most significant drivers of the Gemcitabine market. The drug’s ability to effectively target rapidly dividing cells and its efficacy in combination with other chemotherapeutic agents have made it a preferred choice for many oncologists. Furthermore, ongoing research into the use of Gemcitabine in combination with newer agents, such as checkpoint inhibitors and targeted therapies, is expanding its therapeutic scope and offering improved outcomes for patients. This has led to a surge in clinical trials and new approvals, which are further strengthening its market position. Additionally, the development of generic and biosimilar versions of Gemcitabine is making the drug more affordable, thereby increasing its adoption, especially in cost-sensitive markets.

Another key growth driver is the rising healthcare expenditure in emerging economies, which is enabling greater access to cancer treatments. Countries like China and India, which are witnessing a surge in cancer incidence, are making significant investments in healthcare infrastructure and oncology care, creating new opportunities for the Gemcitabine Hydrochloride market. Pharmaceutical companies are responding to these trends by forming strategic alliances and investing in local production facilities to cater to the growing demand. Moreover, the increasing focus on early diagnosis and treatment of cancer, supported by government screening programs and awareness campaigns, is leading to higher detection rates and, consequently, increased usage of effective chemotherapeutic agents like Gemcitabine. Lastly, the inclusion of Gemcitabine in international cancer treatment guidelines and the strong support from leading health organizations are enhancing its credibility and driving its adoption across diverse healthcare settings, ultimately contributing to sustained market growth.

Select Competitors (Total 44 Featured) -

• Abbexa
• Accord Healthcare, Inc.
• BioCrick BioTech
• Cayman Chemical Company
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• Fresenius Kabi USA
• LGC Standards
• LKT Laboratories, Inc.
• Merck KGaA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Gemcitabine Hydrochloride - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Cancer Propels Demand for Gemcitabine Hydrochloride
  • Case Overview: Growing Demand for Generic Chemotherapeutic Agents Spurs Market Growth
  • Focus on Enhancing Chemotherapeutic Efficacy Strengthens Business Case for Gemcitabine Hydrochloride
  • Rising Healthcare Infrastructure Development in Emerging Markets Expands Market Opportunities
  • Case Overview: Growth in Home Chemotherapy and Outpatient Cancer Care Expands Market for Gemcitabine Hydrochloride
  • Technological Advancements in Liposomal and Nanoparticle-Based Delivery Systems Propel Market Growth
  • Case Overview: Rising Adoption of Gemcitabine in Palliative Care and Symptom Management Strengthens Market Demand
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gemcitabine Hydrochloride Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gemcitabine Hydrochloride by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Gemcitabine Hydrochloride by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Branded Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Cancer Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Non-Small Cell Lung Carcinoma (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Non-Small Cell Lung Carcinoma (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Non-Small Cell Lung Carcinoma (NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Other Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• JAPAN
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• CHINA
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: China 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: China 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• EUROPE
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Gemcitabine Hydrochloride by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Gemcitabine Hydrochloride by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• FRANCE
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: France 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: France 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: France 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• GERMANY
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Gemcitabine Hydrochloride by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Gemcitabine Hydrochloride by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• INDIA
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 169: India 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 172: India 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 175: India 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Gemcitabine Hydrochloride by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Gemcitabine Hydrochloride by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Gemcitabine Hydrochloride by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Gemcitabine Hydrochloride by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030
• AFRICA
  • Gemcitabine Hydrochloride Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Gemcitabine Hydrochloride by Drug Type - Generic Drugs and Branded Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Gemcitabine Hydrochloride by Drug Type - Percentage Breakdown of Value Sales for Generic Drugs and Branded Drugs for the Years 2014, 2024 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Gemcitabine Hydrochloride by End-Use - Other End-Uses, Hospitals End-Use and Cancer Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Gemcitabine Hydrochloride by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use and Cancer Centers End-Use for the Years 2014, 2024 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Gemcitabine Hydrochloride by Condition - Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Gemcitabine Hydrochloride by Condition - Percentage Breakdown of Value Sales for Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Carcinoma (NSCLC) and Other Conditions for the Years 2014, 2024 & 2030

IV. COMPETITION